Case-Based Peer Perspective

This video series has been produced independently by Dermatology Times and supported through an educational grant by Sun Pharmaceuticals.

The panel reviews the expanding landscape of systemic therapy options for advanced cutaneous squamous cell carcinoma, including chemotherapy, EGFR-targeted therapy, and immune checkpoint inhibitors. Drs. Chandra, Carr, and Patel discuss the mechanistic differences between PD-1 and PD-L1 inhibitors, including the potential role of cosibelimab and the current limitations of comparative clinical data. The faculty also examines the practical factors that influence immunotherapy selection, such as available efficacy data, dosing schedules, institutional experience, and formulary considerations. The discussion concludes by highlighting how treatment intent, whether neoadjuvant or definitive, shapes systemic therapy decision-making in clinical practice.

Board-certified dermatologist Tina Bhutani-Jacques, MD, walks through three real-world plaque psoriasis cases to show how disease location, treatment history, and patient preference guide the choice between steroidal and non-steroidal topicals. The series covers the shifting definition of disease severity, formulation strategies for hard-to-treat sites, and practical adherence-building techniques for long-term management.

This Case-Based Peer Perspectives program features Dr. Lauren Madigan exploring the complexities of systemic mastocytosis, from its genetic drivers and multisystem manifestations to the critical role of dermatologists in early identification. Through clinical case studies, she highlights the evolution of management from traditional supportive care to transformative, targeted KIT inhibitors that address the significant quality-of-life and safety risks associated with the disease.

In this Dermatology Times Case-Based Peer Perspectives discussion, Hilary Baldwin, MD, of the Acne Treatment and Research Center in Brooklyn, New York, leads a practical exploration of personalized topical acne management through 3 patient case studies. The series emphasizes tailoring therapy to patient age, lifestyle, skin type, and treatment history, while balancing efficacy, tolerability, and adherence. Across adolescent and adult cases, Baldwin discusses how to optimize outcomes through smart combinations—such as retinoids, benzoyl peroxide, and clascoterone—and patient education. The program highlights strategies to build trust, enhance adherence, and transition between therapies for sustainable long-term control of acne.

Gil Yosipovitch, MD, discusses how prurigo nodularis represents one of the most severe itching conditions in dermatology and how recent advances in targeted biologic treatments like dupilumab and nemolizumab have revolutionized patient care by effectively breaking the itch-scratch cycle and dramatically improving quality of life for patients who previously had limited treatment options.

Omar Noor, MD, FAAD, discusses how personalizing psoriasis treatment requires matching therapy to the individual patient rather than just the disease, considering factors such as adherence challenges, lifestyle, comorbidities, and access to care, while emphasizing the benefits of in-office biologic administration and shared decision-making to optimize treatment outcomes.

Tiffany Mayo, MD, FAAD, discusses how to personalize systemic treatment approaches for atopic dermatitis by considering patient-specific factors, including age, comorbidities, disease impact, lifestyle preferences, and the importance of shared decision-making when selecting between biologics and JAK inhibitors.

An expert explores how prognostic gene expression testing enhances risk stratification and guides personalized treatment in melanoma and squamous cell carcinoma, and also shares clinical insights and practice pearls from my experience using these tests.

Susan Taylor, MD, FAAD, discusses a review of the management of alopecia areata through patient cases. She examines real-world scenarios and addresses some of the challenges that are commonly encountered when treating severe alopecia areata. Throughout the discussion, she shares some of her own practice-based insights and strategies for optimizing patient care in alopecia areata.

A dermatology expert provides comprehensive insights into prurigo nodularis, discussing its disproportionate impact on middle-aged adults and immunocompromised individuals, the evolution of treatment from traditional dermatologic therapies to FDA-approved biologics (dupilumab and nemolizumab), and the importance of addressing both the physical symptoms and psychological burden while considering patient-specific factors such as comorbidities in treatment selection.

Michael Lewitt, MD, discusses personalized management strategiesfor plaque psoriasis (PsO) through comprehensive case studies, highlighting treatment approaches for diverse patients, including a new mother seeking needle-free options, a 55-year-old man with psoriatic arthritis (PsA) and PsO, and a 7-year-old child with a recent PsO diagnosis, emphasizing the importance of tailored therapies based on each patient’s lifestyle, age, and specific needs.

Benjamin Lockshin, MD, FAAD,explores personalized treatment strategies for plaque psoriasis in diverse patient populations, addressing factors such as age, gender, ethnicity, and affected body areas to optimize therapeutic outcomes and patient quality of life.

Pearl E. Grimes, MD,discusses managing long-standing vitiligo through various strategies, including combination therapies for stabilization and repigmentation, OTC solutions for facial involvement, and the evolving role of FDA-approved topical ruxolitinib in redefining treatment paradigms.

Terry Faleye, PA-C, explores advanced vitiligo management strategies, discussing treatment optimization, patient-centered approaches, emerging therapies, and clinical challenges to improve outcomes and quality of life for individuals with this condition.

E. James Song, MD, FAAD, presents patient cases, discusses clinical practices, and provides comprehensive insights on the treatment landscape for plaque psoriasis.

Ted Lain, MD, MBA, FAAD discusses various aspects of vitiligo management through case-based discussions and insights including navigating emotional and clinical challenges to balancing treatment options with coverage constraints.

Jayme Heim, MSN, FNP-BC, presents case studies on atopic dermatitis management, discussing treatment strategies for patients of different ages and genders, while emphasizing the limitations of OTC corticosteroids and exploring the optimization of topical JAK inhibitors.

Andrea Rosik, PA-C, a key opinion leader, explores the challenges associated with atopic dermatitis while examining novel therapies recently approved by the FDA and non-steroidal topical treatments.

Omar Noor, MD, FAAD, a leading dermatologist, provides comprehensive insights on plaque psoriasis management, covering personalized non-steroidal approaches, patient counseling, and the potential of tapinarof as an extended-relief topical treatment.

Andrew Alexis, MD, MPH, recaps a recent Case-Based Roundtable meeting in which patient cases prompted a comprehensive discussion on vitiligo treatment practices.

Latanya Benjamin, MD, FAAD, FAAP, recaps a recent Case-Based Roundtable discussion on the practical management of vitiligo, highlighting two patient cases and providing clinical insights on treatment practices.

James Del Rosso, DO an expert on the management of acne, recaps a recent Case-Based Roundtable discussion, highlighting a complex patient case and providing insights on available therapies and treatment practices.

Hilary Baldwin, MD, presents two case studies of young patients with moderate acne, detailing her personalized treatment approach and sequencing for each case, emphasizing the importance of tailoring treatment plans for optimal outcomes.

Mona Shahriari, MD, FAAD, analyzes two atopic dermatitis cases, exploring the treatment strategies implemented that ultimately resulted in successful resolution of the condition.

Anthony Nuara, MD, PhD, reviews complex cases of two patients with vitiligo and provides his clinical insights on the nuanced factors and disease characteristics that inform his treatment decisions for this condition.